Trevi Therapeutics Inc
NASDAQ:TRVI

Watchlist Manager
Trevi Therapeutics Inc Logo
Trevi Therapeutics Inc
NASDAQ:TRVI
Watchlist
Price: 10.51 USD -4.11%
Market Cap: $1.3B

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
US
Trevi Therapeutics Inc
NASDAQ:TRVI
1.3B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
975.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
549.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.1B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219.1B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.7B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.2B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.3B EUR
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Trevi Therapeutics Inc
Glance View

Market Cap
1.3B USD
Industry
Pharmaceuticals

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. The company is headquartered in New Haven, Connecticut and currently employs 24 full-time employees. The company went IPO on 2019-05-07. The firm is engaged in developing Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The company is also developing Haduvio in levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. The company is conducting a Phase 2b/3 clinical trial of Haduvio in patients with severe pruritus associated with prurigo nodularis. The company is also conducting a Phase 2 clinical trial of Haduvio for chronic cough in patients with IPF. The company has also commenced a Phase 1b clinical trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics of Haduvio in this population. The Company’s nalbuphine ER development programs are Chronic Pruritus, Pruritus in Chronic Liver Disease and Uremic Pruritus Programs.

TRVI Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top